MedTrace Logo

Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.

NCT03424330 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-12-12

No results posted yet for this study

Summary

The study aims to evaluate the safety, usability and efficacy of the ReX-C - a novel medication management system - in measurement and improvement of adherence, in patients receiving oral anti-coagulation therapy for the treatment and prevention of thromboembolism.

Conditions

  • Thromboembolism

Interventions

DEVICE

ReX-C intervention

Patients receive medication by the ReX-C device

OTHER

Standard of Care

Patients receive medication as usual

Sponsors & Collaborators

  • Dosentrx Ltd.

    lead INDUSTRY

Principal Investigators

  • Meir Preis, MD · Carmel Medical Center, Haifa, Israel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-09
Primary Completion
2023-12-25
Completion
2023-12-25

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03424330 on ClinicalTrials.gov